Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Maxcyte (MXCT) Income from Continuing Operations (2020 - 2025)

Maxcyte (MXCT) has disclosed Income from Continuing Operations for 6 consecutive years, with 12416000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Income from Continuing Operations fell 7.43% to 12416000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 45631000.0, a 27.69% decrease, with the full-year FY2024 number at 41055000.0, down 8.26% from a year prior.
  • Income from Continuing Operations was 12416000.0 for Q3 2025 at Maxcyte, roughly flat from 12357000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 2680400.0 in Q3 2021 to a low of 12416000.0 in Q3 2025.
  • A 5-year average of 8245547.37 and a median of 9375000.0 in 2024 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: surged 42.76% in 2022, then crashed 167.55% in 2023.
  • Maxcyte's Income from Continuing Operations stood at 4874600.0 in 2021, then increased by 1.33% to 4809600.0 in 2022, then decreased by 9.74% to 5278000.0 in 2023, then plummeted by 100.78% to 10597000.0 in 2024, then dropped by 17.17% to 12416000.0 in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Income from Continuing Operations are 12416000.0 (Q3 2025), 12357000.0 (Q2 2025), and 10261000.0 (Q1 2025).